Scaling Impactful
Digital Health

Welldoc’s digital health platform, featuring the award-winning BlueStar for diabetes, scales a virtual channel of care across your population.

Why Welldoc's technology of tomorrow belongs in your chronic condition management strategy, today

Studies in type 2 diabetes

12-month randomized-controlled clinical trial

In a prospective, randomized, controlled study, Quinn et al. (Diabetes Care, 2011) found that, individuals with type 2 diabetes whose A1C levels were poorly controlled (>9.0%) or abnormal (7.5-8.9%) at the time of enrollment, and who were randomized to use a mobile phone app to help them manage their diabetes in addition to usual care, improved A1C by an average 1.9%, compared with 0.7% improvement in persons randomized to usual care alone, a difference of 1.2% (P < 0.001) over 12 months.


  • Primary endpoint: change in A1C over one year
  • Randomization to one of four groups: (1) usual care (n=56), (2) usual care plus patient mobile app/access to web portal for diabetes management (n=23), (3) usual care, mobile app/portal for patient, plus provider access to raw patient data (n=22), and (4) usual care, mobile app/portal for patient, plus patient data tied to decision support for their physician (n=62)
  • 213 patients enrolled; 163 included in the analysis

Study Limitations

  • Private insurance only
  • Study dropout rates required use of mixed-effects statistical modeling to impute missing

Study Results

The results from the study (Figure 1) indicate a hemoglobin A1C reduction of 1.9%, compared with 0.7% improvement in persons randomized to usual care alone, a difference of 1.2% (P < 0.001) over 12 months. The results stratified on baseline glycated hemoglobin show that the results in Figure 1 do not indicate regression to the mean. Figure 2 shows the results within strata of baseline A1C less than 9%, and Figure 3 shows the results within strata of baseline A1C greater than or equal to 9%.

line graph showing average hemoglobin A1C reduction over 12 months. See description for more information

3-month randomized-controlled clinical trial

In a prospective, randomized, controlled study, Quinn et al. (Diabetes Technology and Therapeutics, 2008) found that individuals whose A1C levels were greater than or equal to 7.5% within most recent three months and received Welldoc’s software experienced an average decrease in A1c of 2.03%. Patients in the control group obtained an average A1C reduction of  0.68% (P < 0.02, one-tailed). Of the intervention patients, 84% had medications titrated or changed by their HCP compared to controls (23%, P = 0.002).


  • Primary Endpoint: change in A1C over three months and change in prescribing behavior
  • Randomization to one of two groups: usual care (n=15) and usual care plus BlueStar (n=15)
  • 30 patients enrolled; 26 included in the analysis

Study Limitations

  • Small study size

Over 45 Clinical Publications

Welldoc rigorously examines its products and their impact, as evidenced in over 45 peer-reviewed publications, posters, and presentations.

Clinical Studies

Clinical Studies Diabetes Technology Therapeutics

Older Adult Self-Efficacy Study of Mobile Phone Diabetes Management.


Clinical Studies Journal of Diabetes Science and Technology

Mobile Diabetes Intervention for Glycemic Control: Impact on Physician Prescribing.


Demonstration Project


Frameworks Encore Presentation at AADE 2018

Technology-Enabled Diabetes Self-Management Education & Support


Frameworks American Association of Diabetes Educators

Expanding reach: AADE7 moves into the digital space


Data Analytics

Data Analytics Diabetes Technology Society, San Francisco

Type 2 Diabetes Hypoglycemia Prediction: Using SMBG Data & Probabilistic Methods


Data Analytics AADE, Baltimore

Use of patient-generated health data


EMR Integration

EMR Integration Journal of Diabetes Science and Technology

Integration of a mobile-integrated therapy with electronic health records: lessons learned.


Whitepapers & Articles

Whitepapers & Articles Canadian Medical Association Journal (CMAJ)

How ‘digital therapeutics’ differ from traditional health and wellness apps


Whitepapers & Articles mHealth

Technology to overcome therapeutic inertia


Clinical Models

Clinical Models AADE, New Orleans

Educators: Go Mobile & Join the Digital Revolution!


Clinical Models AADE In Practice

Are You Ready to Be an eEducator?


Book Chapters

Book Chapters mHealth Innovation: Best Practices from the Mobile Frontiers

A. Case Study: Mobile prescription therapy


Book Chapters Connected Health: Improving Care, Health, and Efficiency with Wearables

Case Study: The IoT and Big Data in Healthcare Unleashing the Next Generation of Value Creation


Real World Studies

Real World Studies Diabetes Technology Society, Bethesda, MD

Determinants of Engagement in Digital Health: What Makes it Stick?


Real World Studies Diabetes Technology Society, Washington D.C.

A Data Science Framework for Mobile Health–Engagement and Outcomes


The impact of A1C reduction on cost savings

To test the relationship between A1C reduction and cost savings, we funded a retrospective analysis in partnership with IBM Watson Health. We provided IBM Watson Health starting and ending A1C data from 3,000+ of our BlueStar users. Documented A1C reductions associated with BlueStar are correlated with cost differences associated with the factors listed below.

Hospitalizations, ER visits, and HCP office visits

Cost of devices, supplies,
and medications

Cost of co-morbid complications
of diabetes

Study Population

Claims data from patients in the IBM Watson Health's Market Scan Database, which captures claims data of more than 200 million individuals in the US.

Did you know?

The CDC predicts 1 out of every 3 people born in the US after the year 2000 will develop diabetes.

Study Findings

Once the patients were stratified by A1C band, the analysis was customized for the commercial sector and the Medicare sector.

Segment by Starting A1C Bands
For All Bands with A1C ≥ 7
For All Bands with A1C ≥ 8
For A1C ≥ 9
Commercial Sector
Estimated cost savings per patient, annually
Medicare Sector
Estimated cost savings per patient, annually

Truven MarketScan Database: Annual Cost Per Patient is average amount paid for any healthcare claim within 365 days for: 1) patients with at least two lab results within the same A1c range ; and 2) patients with four lab results within the same A1C range. Percentage in Band Today is based on national attrition levels in Truven database.

Estimate how much diabetes costs your organization

Enter the number of members to the right for an estimation of the annual cost of diabetes in your population.

Estimate provided indicates average cost of diabetes within a commercial population as derived from IBM Watson Health retrospective analysis funded by Welldoc, Inc.

Request a free copy of IBM Watson Health's white paper

Click below to visit our contact us page, where you can request a copy of the white paper. Inside, you will find more information related to how we arrived at cost reductions by A1C band.

Contact Us

Fully HIPAA compliant


ISO 13485 certified

ISO 13485

FDA cleared

FDA Cleared,
seven 510Ks, Rx and OTC IFU

SOC 2 certified


Choose a tool your members and providers will love

"I can tell that diabetes experts are a part of this and have really honed in on what people need."

Candy Barnes, BlueStar User

What makes our products different

What makes all of Welldoc’s software unique? There are a lot of tools that sound similar to ours out there, but no other solution is device agnostic, empowers the user’s existing care team, and scales at a population level.

Lean More about BlueStar

Device Agnostic

We integrate seamlessly into your member’s life, allowing them to bring their own device instead of the one provided.

Empower the user's existing care team

Illuminate data between in-office visits to facilitate better decision making and more productive visits.

Easily scales at population level

AI-driven coaching reserves human touch-points for higher needs members

Our Team is Ready to Assist Implementation

  • Implementation

    Our seasoned implementation leads help you choose a plan we are confident will succeed.

  • Marketing

    Our marketing team develops a plan to engage your unique population.

  • Strategy

    Our data scientists build models to forecast your ROI and engagement.

  • Clinical Team

    Our clinical experts ensure you have science to back up your decision.